A study on lorlatinib in ROS1-positive NSCLC patients showed that those with p53 mutations had a PFS of 8.5 months, while those with p53 wild-type had a PFS of approximately 23.6 months [64]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.